Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

‘No More Questions’ On Scrutiny As EU Talks Set To Give Notified Bodies Yet More Responsibility

This article was originally published in Clinica

Executive Summary

While it is premature to speak of agreement, it seems that the three parties involved in negotiating the future EU medtech regulations have reached a point where there are “no outstanding questions any more” on one of the biggest sticking points – the scrutiny of high-risk medical devices. However, Clinica understands that this is not yet the case for scrutiny of in vitro diagnostics.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT103283

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel